

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/832,517	04/09/2001	Victor D. Dolecek	P9530	1193
75	90 04/08/2003			
Steven C. Petersen Hogan & Hartson LLP One Tabor Center			EXAMINER	
			REIFSNYDER, DAVID A	
1200 17th Stree Denver, CO 80			ART UNIT PAPER NUMBER	
,			1723	14
			DATE MAILED: 04/08/2003	. /

Please find below and/or attached an Office communication concerning this application or proceeding.

				AS-14			
,		Application No.	Applicant(s)				
	Office Action Commany	09/832,517	DOLECEK ET AL.				
	Office Action Summary	Examiner	Art Unit				
	The state of this communication and	David A Reifsnyder	1723				
Period fo	• •						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)🛛	<u> </u>						
2a)⊠		nis action is non-final.					
3)	Since this application is in condition for allowa closed in accordance with the practice under <i>E</i>						
Dispositi	tion of Claims	Ex parto Quayio, 1000 C.E.	, 400 0.0. 210.				
4)⊠	Claim(s) 33-52 is/are pending in the application	n.					
	4a) Of the above claim(s) is/are withdraw	wn from consideration.					
5)	Claim(s) is/are allowed.						
6)⊠	Claim(s) 33-52 is/are rejected.						
7)	Claim(s) is/are objected to.						
	8) Claim(s) are subject to restriction and/or election requirement.  Application Papers						
	The specification is objected to by the Examiner	<b>:Г</b> .					
<i>,</i> —	The drawing(s) filed on <u>09 April 2001</u> is/are: a)		y the Examiner.				
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) 🗌 .	11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
	If approved, corrected drawings are required in rep	ρly to this Office action.					
12)	The oath or declaration is objected to by the Exa	aminer.					
Priority (	under 35 U.S.C. §§ 119 and 120						
13)	Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C. § 119	∂(a)-(d) or (f).				
a)[	All b) Some * c) None of:						
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
	Acknowledgment is made of a claim for domestic	·		/ <sub>4</sub>			
a) ☐ The translation of the foreign language provisional application has been received.							
15)×	15)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachmen		C Internitura Cuma					
2) Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mnation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>12</u>	5) Notice of Inform	nary (PTO-413) Paper No(s) nal Patent Application (PTO-152)				
I S. Patent and T	Trademark Office		Post of Posses No. 14				

Art Unit: 1723

#### **DETAILED ACTION**

### Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 33-52 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Holm et al. (see figures 1-3 and the Example)

Claims 33-52 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Antanavich et al. (see the claims)

Claims 33-52 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by WO 91/09573.

# Response to Arguments Regarding Holm et al.

Applicant's arguments filed in his remarks on January 23, 2003 regarding the Holm et al. anticipatory rejection have been fully considered but they are not persuasive.

Art Unit: 1723

In response to applicant's argument in his remarks on page 3, lines 5-14 that Holm et al. fails to show certain features of applicant's invention as defined in independent claim 33, it is noted that the features upon which applicant relies (i.e. that his chamber is separate from his centrifuge) are not recited in the rejected claims.

Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988

F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

The applicant argues in his remarks on page 3 lines 13 that Holm et al. does not teach a system for preparing an autologous thrombin. Furthermore, the applicant states on page 3 lines 29 to 31 that Holm et al.'s system includes a filter; however, the applicant argues in his remarks on page 3, lines 13 to 14 that dependent claim 34 further defines his invention by claiming a filter <u>for separating autologous thrombin from a clot.</u> In response to both of those arguments, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

Art Unit: 1723

## Response to Arguments Regarding Antanavich

Applicant's arguments filed in his remarks on January 23, 2003 regarding the Antanavich anticipatory rejection have been fully considered but they are not persuasive.

The applicant argues in his remarks on page 4 lines 16 to 17 that Antanavich does not teach a system for preparing an autologous thrombin. Furthermore, the applicant states on page 4, lines 5 to 14 that Antanavich teaches two chambers with each of his chambers having a filter; however, the applicant argues in his remarks on page 4, lines 19 to 20 that Antanavich fails to teach a filter <u>for separating thrombin from a clot.</u> In response to both of those arguments, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

## Response to Arguments Regarding WO 91/09573

Applicant's arguments filed in his remarks on January 23, 2003 regarding the WO 91/09573 anticipatory rejection have been fully considered but they are not persuasive.

The applicant argues on page 5 lines 3 to 4 that WO 91/09573 does not teach a system for preparing an autologous thrombin. Furthermore, it is noted that WO

Art Unit: 1723

91/09573 specification teaches a filter in on page 17, lines 5 to 10; however, the applicant argues in his remarks on page 5, line 6 that WO 91/09573 fails to teach a filter for separating thrombin from a clot. In response to both of those arguments, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

#### Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David A Reifsnyder whose telephone number is 1-703-308-0456. The examiner can normally be reached on M-F 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Wanda M Walker can be reached on 1-703-308-0457. The fax phone numbers for the organization where this application or proceeding is assigned are 1-703-872-9310 for regular communications and 1-703-872-9311 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 1-703-308-3601.

David A Reifsnyder
Primary Examiner
Art Unit 1723

DAR April 3, 2003